Ruth M. O’Regan, MD, focuses on identifying mechanisms of resistance to breast-cancer therapies and the development of new therapies with a specific focus on triple negative breast cancer. She has led several trials focused on new therapeutic approaches for breast cancers resistant to standard therapies.
Dr. O'Regan earned her medical degree from University College Dublin. She completed her internal medicine residency at the Medical College of Wisconsin and her hematology/oncology fellowship at Northwestern University.